Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc's innovative approach to developing allogeneic gamma delta T cell therapies positions the company favorably within the biotechnology sector, particularly with its lead candidate ADI-001 showing promising efficacy in treating autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The anticipated Phase 1 study of ADI-212 for metastatic castration-resistant prostate cancer, set to begin in 2026, may further expand the company's oncology portfolio, potentially enhancing its market presence. Additionally, Adicet's strategy to contract third-party manufacturers for commercial-scale production is expected to mitigate manufacturing risks, thereby strengthening its operational efficiency and overall market appeal.

Bears say

Adicet Bio Inc. faces a challenging financial outlook, projecting a net loss of $1.13 per share for 2025 due to various risks associated with its lead product candidate, ADI-001. Concerns about the lower efficacy of ADI-001 in patients with prior anti-CD20 therapy failures, alongside heightened competition, may adversely impact market share and revenue potential. The company also confronts significant regulatory hurdles, having not yet obtained FDA approval for its gamma delta T-cell therapies, compounded by lowered success probabilities for its other candidates and increased discount rates reflecting a more conservative stance on future financial performance.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.